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Abstract. Between 1955 and the end of 1967, the framework of clinical transplantation that exists 
today was established in a small number of centers in continental Europe, Great Britain, and the 
United States, At first, the primary organ was the kidney, but efforts to transplant the kidney soon 
strongly influenced the development of liver and ultimately all other kinds of organ transplantation, 
This paper reviews the pertinent history of these developments as outlined in a lecture given in Janu-
ary 2003 in Bangkok on the occasion of the Prince Mahidol Award for a life's work in the field of 
organ transplantation, 
DEVELOPMENT OF THE LIVER 
OPERATION 
Liver transplantation was not mentioned in 
the literature until 1955 when C Stuart Welch of 
Albany Medical College described the insertion 
of an auxiliary hepatic allograft in the right 
paravertebral gutter of dogs, without disturbing 
the native liver (Welch, 1955), Three years later, 
total recipient hepatectomy and liver replacement 
in dogs was accomplished independently at 
Northwestern University in Chicago (Starzl et aI, 
1960) and at Harvard University in Boston 
(Moore et ai, 1960), I first met the leader of the 
Boston team, Francis D Moore, at the 1960 meet-
ing of the American Surgical Association, where 
I discussed his presentation of 31 dog experi-
ments, By then, our total experience with this pro-
cedure had increased to 80, 
The same two prerequisites for perioperati ve 
survival after canine liver replacement were iden-
tified in thc two laboratories, The first was pre-
vention of ischemic injury to the allograft. This 
was made possible in Boston by immersing the 
liver in iced saline (Moore et aI, 1960). In con-
trast, our liver allografts were cooled by the in-
travascular infusion of chilled solutions in much, 
the same way as in clinical practice today (Starzl 
et aI, 1960). The second prerequisite was avoid-
ance of damage to the recipient splanchnic and 
systemic venous beds, the drainage of which was 
obstructed during host hepatectomy and graft 
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implantation. This was accomplished with de-
compressing external venovenous bypasses 
(Moore et aI, 1960; Starzl et aI, 1960). 
These studies defined almost to the last de-
tail the liver replacement operation (Fig I) soon 
to be performed in humans. Also, by the end of 
1959, we had developed the operation of 
multivisceral transplantation (Starzl and Kaupp, 
1960). Here, the allograft consisted of the liver 
and all of the other intraperitoneal organs (Fig 
2). The multivisceral operation and its modifica-
tions (Fig 3) were not applied in humans until 30 
years later but they are now part of the conven-
tional armamentarium of advanced organ trans-
plant centers. 
IMMUNOSUPPRESSION 
These procedures were perfected between 
1958-1960, preceding the availability of immu-
nosuppression. All of the allografts in the unmodi-
fied animals were rejected within 3 weeks, usu-
ally after 5-10 days. Because the immune barrier 
to allografts as was thought by most immunolo-
gists to be impenetrable, our surgical research was 
considered by many critics to be naIve or waste-
ful. 
Host cytoablation 
Just as it was losing momentum, the work 
in liver transplantation was revitalized by 6 suc-
cessful human kidney transplantations performed 
between January 1959 and February 1962: the 
first in Boston and the next 5 in Paris (summa-
rized in Starzl, 2002). All 6 renal recipients had 
been conditioned prior to transplantation with 
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sublethal doses of 450R total body irradiation. It 
quickly became apparent, however, that the Bos-
ton and French successes with the kidney, remark-
able though they were, would not be a bridge to 
liver transplantation. Total body irradiation pre-
cluded even perioperative, much less extended, 
survival of canine liver recipients (Starzl et aI, 
1962). 
Drug immunosuppression 
A sea change occurred with the arrival of 
the drug 6-mercaptopurine (6-MP)(Schwartz and 
Dameshek, 1959; 1960), and its derivative aza-
thioprine. The drugs were first tested in a rabbit 
skin graft model (Schwartz and Demeshek, 1960) 
and subsequently by Roy CaIne and Charles 
Zukoski in the canine kidney transplant model. 
The results with 6-MP and azathioprine in the first 
clinical trials of kidney transplantation were dis-
appointing in that only one of the first 13 recipi-
ents survived >6 months (Murray et af, 1963; 
Hopewell et ai, 1964). In the exceptional patient, 
whose operation was on April 6, 1962, the kid-
ney was failing after 11 months (Murray et ai, 
1963). However, it was destined to support di-
alysis-free life of the recipient for a total of 17 
months. This was the 7th human to survive more 
than one-year after kidney transplantation, and 
the first to do so without total body irradiation. 
Fig I-Completed liver replacement in the dog. The fact 
that the recipient was a dog rather than a human 
is identifiable only by the multilobar appearance 
of the liver. 
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In the meanwhile, I had moved from North-
western to the University of Colorado (Denver) 
where we had obtained our own supply of aza-
thioprine. We systematically evaluated the new 
drug with the simpler canine kidney model rather 
than with liver transplantation. As in other labo-
ratories, our yield of 100-day canine kidney trans-
plant survivors treated with azathioprine was 
small. However, two crucial findings were clini-
cally relevant. First, kidney rejection develop-
ing in the dog under azathioprine invariably could 
be reversed by the addition of large doses of pred-
nisone (Marchioro et ai, 1964). Second, mean 
survival of the dog recipients was doubled when 
the animals were treated with the drug before as 
well as after operation (Starzl,1964). 
We now undertook clinical trials of kidney 
and liver transplantation, in that order. Daily doses 
of azathioprine were give for one to two weeks 
before as well as after transplantation, with the 
addition of prednisone only to treat rejection. The 
two features of the adaptive immune response to 
allografts that eventually would make transplan-
tation of all kinds of organs feasible and practical 
were promptly recognized in kidney recipients. 
These were described in the title of the report of 
the first Colorado kidney recipients (Starzl et ai, 
1963 b): first, the reversibility of rejection, and 
Fig 2 -Canine multivisceral transplantation. The organs 
of the composite allograft are not shaded. With 
permission of Surg Forum 1960; 11 :28-30. 
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Fig 3-The original canine multi visceral allograft (bot-
tom center) and some of its variations (arrows) 
that are used clinically today. 
Immunosuppression (1962-1963) 
Prednisone 
Azathioprine 
Tolerance 
Tx 
Fig 4- The strategy of double drug immunosuppression 
used for kidney transplant recipients in 1962-63. 
Note the reversal of rejection with the addition 
of prednisone to azathioprine. More than a third 
of a century later, it was realized that the timing 
and dosage policy of drug administration had 
been in accord with the principles oftolerogenic 
immunosuppression that were elucidated after 
the mechanisms of organ engraftment and ac-
quired tolerance were discovered since 1992. 
more importantly, the subsequent development of 
donor specific tolerance. "Tolerance" referred to 
the time-related decline of need for maintenance 
immunosuppression (Fig 4). Although the maxi-
mum follow-up of our first human renal trans-
plantations was only six months in the Spring of 
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1963, nine of these patients still bear their origi-
nal kidney allografts after 40 years and are the 
longest surviving allograff recipients in the world 
(Starzl, 2002). 
HUMAN LIVER REPLACEMENT: 1963 
Armed with the early kidney experience, the 
first attempt at liver transplantation was made on 
March 1, 1963, with a ventilator-bound child with 
biliary atresia. The patient bled to death during 
operation. The next 2 recipients, both adults. died 
22 and 7.5 days after their transplantations on May 
5 and June 3, 1963 for the indication of primary 
liver malignancies (Starzl et ai, 1963a). As in 
kidney recipients, rejections were easily reversed 
with prednisone. Although the 2 adult operations 
were technically satisfactory, emboli formed in 
the bypass tubing of the veno-venous bypasses, 
migrated to the lungs, and caused or contributed 
to the deaths of these recipients. 
During the last half of 1963, four more at-
tempts to replace the human liver were made: two 
in Denver, and one each in Boston and Paris (sum-
marized in Starzl, 2002). Clinical activity then 
ceased for 3-112 years. The worldwide morato-
rium was voluntary. The decision to stop was 
reinforced, however, by widespread criticism of 
attempting to replace an unpaired vital organ with 
an operation that had come to be perceived as too 
difficult to ever be tried again. In contrast, kid-
ney transplantation thrived at the University of 
Colorado and elsewhere. 
THE LIVER MORATORIUM 
Advances were made during the moratorium 
that were applicable to all organs. First, it was 
shown, in a clinical collaboration with Paul 
Terasaki of UCLA that the quality ofHLA match-
ing short of perfect compatibility had little asso-
ciation with kidney transplant outcome. It could 
be assumed that the same would apply to the liver 
and to the other non-renal organs. Second, anti-
lymphocyte globulin (ALG) was prepared from 
mouse antilymphocyte serum (ALS) and intro-
duced clinically. Third, it was established that or-
gans other than the kidney (especially the liver) 
could induce tolerance. Finally, an ex vivo perfu-
sion system was developed in 1966 and 1967 that 
permitted reliable preservation of canine livers 
and other organs for as long as a day. Now, it 
was time to try liver transplantation again. 
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THE RESUMPTION OF HUMAN LIVER 
REPLACEMENT 
When the liver program reopened in July, 
1967, multiple examples of prolonged human 
liver recipient survival were produced, under 
triple drug immunosuppression: azathioprine, 
prednisone, andALG (Starzl et aI, 1968). The liver 
transplant beachhead was reinforced by the open-
ing of Roy CaIne's clinical program in Cam-
bridge, England, in February 1968. Transplanta-
tion of other extrarenal organs followed close 
behind the liver, using similar immunosuppres-
sion (catalogued in Starz!, 2002). Hearts were 
successfully transplanted in 1968 in Capetown by 
Christian Barnard, and in Palo Alto by Norman 
Shumway. In 1969, the first prolonged survival 
after human lung and pancreas transplantation 
was accomplished in Ghent and Minneapolis, re-
spectively. 
THE ARRIVAL OF BETTER DRUGS 
Despite these successes, the widespread use 
of the liver and other extrarenal organs, and even 
of cadaveric kidneys, was precluded for another 
decade by the high mortality. The outlook for all 
organs improved with the advent of cyclosporine 
in 1978, and again when tacrolimus was substi-
tuted for cyclosporine in the 1990's. By the end 
of the 20th century. transplantation of the liver and 
all of the other vital organs had become an inte-
gral part of sophisticated medical practice in ev-
ery developed country in the world. 
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